<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A brief exposure to the volatile <z:chebi fb="164" ids="38867">anesthetic</z:chebi> <z:chebi fb="0" ids="6015">isoflurane</z:chebi> (preconditioning) induces ischemic tolerance in rat brain </plain></SENT>
<SENT sid="1" pm="."><plain>However, whether <z:chebi fb="0" ids="6015">isoflurane</z:chebi> preconditioning improves long-term neurological outcome after <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> and the mechanisms for this neuroprotection are not known </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we report that <z:chebi fb="0" ids="6015">isoflurane</z:chebi> preconditioning (2% <z:chebi fb="0" ids="6015">isoflurane</z:chebi> for 30 min at 24 h before <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e>) reduced brain <z:mpath ids='MPATH_124'>infarct</z:mpath> sizes and improved neurological deficit scores assessed 6, 24, and 72 h after permanent right middle cerebral <z:mp ids='MP_0006134'>arterial occlusion</z:mp> (MCAO) in adult male rats </plain></SENT>
<SENT sid="3" pm="."><plain>More morphologically intact neurons and fewer dying cells existed in the ipsilateral frontal cortex area 1 and rostral subventricular zone of caudate putamen of <z:chebi fb="0" ids="6015">isoflurane</z:chebi>-preconditioned rats than rats undergoing MCAO alone at 14 days after the MCAO </plain></SENT>
<SENT sid="4" pm="."><plain>This neuroprotection was abolished by an inhibitor of p38 <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinases (MAPK), 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(<z:chebi fb="0" ids="51643">4-pyridyl</z:chebi>)<z:chebi fb="0" ids="16069">1H-imidazole</z:chebi> (SB203580) (the percentages of <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes in the ipsilateral hemisphere volumes were 34 +/- 7% for MCAO, 24 +/- 6% for <z:chebi fb="0" ids="6015">isoflurane</z:chebi> preconditioning plus MCAO, and 30 +/- 6% for SB203580 plus <z:chebi fb="0" ids="6015">isoflurane</z:chebi> preconditioning plus MCAO, n = 8, P &lt; 0.05 for <z:chebi fb="0" ids="6015">isoflurane</z:chebi> preconditioning plus MCAO to compare with MCAO alone or with SB203580 plus <z:chebi fb="0" ids="6015">isoflurane</z:chebi> preconditioning plus MCAO) and mimicked by an activator of these kinases, anisomycin </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="6015">Isoflurane</z:chebi> induced a rapid and prolonged increase of the phosphorylated p38 MAPK in cerebral neocortex </plain></SENT>
<SENT sid="6" pm="."><plain>These active kinases distributed mainly in perikaryal regions of neurons </plain></SENT>
<SENT sid="7" pm="."><plain>These results suggest that <z:chebi fb="0" ids="6015">isoflurane</z:chebi> preconditioning may improve long-term neurological outcome after focal <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> and that the effects may be mediated by activating p38 MAPK </plain></SENT>
</text></document>